# Technical Design Document: CTCF-mediated MYC Oncogene Regulation in Human Cancer Cell Lines

**Project ID:** biology-ctcf-myc-001  
**Date:** 2025-07-08  
**Version:** 1.0  
**Status:** Design Phase  

## 1. Executive Summary

This project investigates the role of CTCF (CCCTC-binding factor) in regulating the MYC oncogene across different human cancer cell lines through computational analysis of publicly available genomic datasets. The study will employ ChIP-seq, RNA-seq, and chromatin accessibility data to characterize CTCF binding patterns, chromatin topology, and their correlation with MYC expression levels.

## 2. Research Objectives and Hypotheses

### 2.1 Primary Objective
Characterize the mechanism by which CTCF binding sites regulate MYC oncogene expression in human cancer cell lines and identify potential therapeutic targets.

### 2.2 Specific Aims
1. **Map CTCF binding landscapes** across multiple cancer cell lines and correlate with MYC expression levels
2. **Identify chromatin loops** mediated by CTCF that influence MYC promoter accessibility
3. **Characterize enhancer-promoter interactions** involving the MYC locus
4. **Compare regulatory mechanisms** between cancer and normal cell lines

### 2.3 Hypotheses
- **H1:** CTCF binding sites create chromatin loops that either enhance or repress MYC expression depending on their genomic context
- **H2:** Cancer cell lines exhibit altered CTCF binding patterns compared to normal cells, leading to MYC dysregulation
- **H3:** Specific CTCF binding motifs near the MYC locus are predictive of expression levels

## 3. Computational Methodology

### 3.1 Data Sources
**Primary Datasets (ENCODE/GEO):**
- ChIP-seq data for CTCF across 15+ cancer cell lines
- RNA-seq expression data for corresponding cell lines
- ATAC-seq chromatin accessibility data
- Hi-C chromatin interaction data (where available)
- Normal tissue controls from GTEx

**Target Cell Lines:**
- HeLa (cervical cancer)
- MCF-7 (breast cancer)
- K562 (leukemia)
- HepG2 (liver cancer)
- A549 (lung cancer)
- Normal counterparts: HUVEC, NHDF, etc.

### 3.2 Bioinformatics Pipeline

#### 3.2.1 Data Acquisition and Quality Control
```bash
# Automated download from GEO/ENCODE
fastq-dump --split-files [SRR_IDs]
fastqc *.fastq
multiqc .
```

#### 3.2.2 ChIP-seq Analysis Pipeline
```bash
# Alignment and peak calling
bowtie2 -x hg38 -U input.fastq | samtools sort > aligned.bam
macs2 callpeak -t aligned.bam -c control.bam -f BAM -g hs -n ctcf_peaks
```

#### 3.2.3 RNA-seq Expression Analysis
```r
# DESeq2 analysis in R
library(DESeq2)
dds <- DESeqDataSetFromMatrix(countData, colData, design = ~ condition)
results <- DESeq(dds)
```

#### 3.2.4 Chromatin Loop Analysis
```python
# HiCExplorer for chromatin interaction analysis
hicFindLoops --matrix interaction.h5 --outFileName loops.bedpe
```

### 3.3 Analysis Framework

#### 3.3.1 CTCF Binding Site Characterization
- Peak annotation relative to MYC locus (±2Mb window)
- Motif analysis using HOMER and MEME-Suite
- Conservation analysis across species
- Binding strength quantification

#### 3.3.2 Expression Correlation Analysis
- Pearson correlation between CTCF binding and MYC expression
- Multiple regression modeling including cofactors
- Time-course analysis where available

#### 3.3.3 Chromatin Architecture Analysis
- Loop calling and validation
- Topologically Associating Domain (TAD) boundary analysis
- Enhancer-promoter interaction mapping

## 4. Expected Outcomes and Deliverables

### 4.1 Primary Deliverables
1. **Comprehensive CTCF binding atlas** for MYC regulation across cancer types
2. **Predictive model** for MYC expression based on CTCF binding patterns
3. **Candidate therapeutic targets** - specific CTCF sites for intervention
4. **Interactive web portal** for data visualization and exploration

### 4.2 Publications
- **Primary paper:** "CTCF-mediated chromatin loops drive MYC oncogene regulation in human cancers"
- **Methods paper:** "Computational pipeline for integrative analysis of chromatin topology and gene regulation"

### 4.3 Code and Data
- **GitHub repository** with complete analysis pipeline
- **Docker container** for reproducible analysis
- **Processed datasets** for community use

## 5. Technical Implementation

### 5.1 Computational Requirements
- **CPU:** 32+ cores for parallel processing
- **Memory:** 128GB RAM for large genomic datasets
- **Storage:** 5TB for raw and processed data
- **Environment:** Ubuntu 20.04 with Conda package management

### 5.2 Software Dependencies
```yaml
# environment.yml
dependencies:
  - python=3.9
  - bioconda::bowtie2
  - bioconda::samtools
  - bioconda::macs2
  - bioconda::homer
  - bioconda::deeptools
  - r-base=4.1
  - bioconductor-deseq2
  - bioconductor-genomicranges
```

### 5.3 Data Management
- **Raw data:** Organized by cell line and assay type
- **Processed data:** Standardized BED/BAM formats
- **Metadata:** Sample tracking with detailed annotations
- **Version control:** Git LFS for large files

## 6. Timeline and Milestones

### Phase 1: Data Acquisition (Weeks 1-2)
- Download and organize datasets from ENCODE/GEO
- Quality control and validation
- **Milestone:** Complete dataset catalog with QC metrics

### Phase 2: Pipeline Development (Weeks 3-6)
- Implement ChIP-seq analysis pipeline
- Develop RNA-seq expression analysis
- Create integration workflows
- **Milestone:** Validated pipeline with test datasets

### Phase 3: Analysis and Discovery (Weeks 7-12)
- Execute full analysis across all cell lines
- Statistical modeling and correlation analysis
- Chromatin loop characterization
- **Milestone:** Complete results with statistical validation

### Phase 4: Validation and Interpretation (Weeks 13-16)
- Independent dataset validation
- Literature comparison and contextualization
- Therapeutic target identification
- **Milestone:** Validated findings ready for publication

### Phase 5: Manuscript and Dissemination (Weeks 17-20)
- Paper writing and figure generation
- Code documentation and release
- Data portal development
- **Milestone:** Submitted manuscript and public resources

## 7. Risk Assessment and Mitigation

### 7.1 Technical Risks
- **Data availability:** Contingency plans for alternative datasets
- **Computational complexity:** Cloud computing backup options
- **Pipeline failures:** Extensive testing and validation

### 7.2 Scientific Risks
- **Negative results:** Frame as mechanistic insights
- **Limited novelty:** Focus on integrative approach and therapeutic implications
- **Reproducibility:** Emphasis on open science and code sharing

## 8. Success Metrics

### 8.1 Scientific Impact
- Novel CTCF binding sites identified: >50
- Validated chromatin loops involving MYC: >10
- Predictive model accuracy: >80%

### 8.2 Publication Metrics
- Target journal: Nature Communications or Cell Reports
- Expected citations: 50+ within 2 years
- Code repository stars: 100+

### 8.3 Community Impact
- Database usage: 1000+ users
- Pipeline adoption: 10+ independent studies
- Therapeutic leads: 2+ validated targets

## 9. Budget and Resources

### 9.1 Personnel (20 weeks)
- Principal Investigator: 0.25 FTE
- Bioinformatics Analyst: 1.0 FTE
- Graduate Student: 0.5 FTE

### 9.2 Computational Resources
- Cloud computing: $5,000
- Software licenses: $1,000
- Data storage: $2,000

### 9.3 Total Estimated Cost: $45,000

## 10. Conclusion

This project represents a comprehensive computational approach to understanding CTCF-mediated MYC regulation in cancer. By leveraging existing high-quality datasets and robust bioinformatics methods, we expect to generate novel insights into oncogene regulation with direct therapeutic implications. The open-science approach ensures broad community impact and reproducibility.

---

**Prepared by:** llmXive Research Team  
**Contact:** research@llmxive.org  
**GitHub:** https://github.com/llmxive/ctcf-myc-regulation
